Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Eiber

Showing results (111-120 of 377) with videos related to

Pageof 38
Sort By:
EJNMMI Research|January 31, 2022
Initial evaluation of [<sup>18</sup>F]-FACBC for PET imaging of multiple myelomaVolker Morath, Michael Heider, Markus Mittelhäuser, et al.
EJNMMI Research|February 3, 2026
Estimation of split renal function using [<sup>18</sup>F]-flotufolastat PET/CT compared with [<sup>68</sup>Ga]-PSMA-11 and [<sup>99m</sup>Tc]-MAG3 scintigraphyMichael Christian Marius Gammel, Charlotte Olufs, Kimberley Hansen, et al.
EJNMMI Physics|December 14, 2021
A population-based method to determine the time-integrated activity in molecular radiotherapyDeni Hardiansyah, Ade Riana, Peter Kletting, et al.
Seminars in Nuclear Medicine|December 9, 2025
The role of non-FDG agents in PET imaging of bladder cancerAlireza Safarian, Dina Muin, Lena Unterrainer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 18, 2025
Impact of baseline <sup>18</sup>F-flotufolastat PET bone tumor volume for prognosticating severe hematologic toxicity in patients with metastatic castration-resistant prostate Cancer receiving <sup>177</sup>Lu-PSMA-targeted radioligand therapyAmir Karimzadeh, Kimberley Hansen, Stefan Hein, et al.
European Urology Oncology|January 5, 2023
Prostate-specific Membrane Antigen-radioguided Surgery Facilitates Pelvic Lymph Node Dissection During Radical Prostatectomy for the Treatment of Locally Advanced Prostate Cancer with Regional Lymph Node MetastasesLukas Lunger, Lisa Steinhelfer, Philipp Korn, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 25, 2023
Delayed Imaging Improves Lesion Detectability in [<sup>99m</sup>Tc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate CancerChristoph Berliner, Lisa Steinhelfer, Maythinee Chantadisai, et al.
EJNMMI Radiopharmacy and Chemistry|February 26, 2024
Preclinical comparison of [<sup>177</sup>Lu]Lu-rhPSMA-10.1 and [<sup>177</sup>Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studiesAlexander Wurzer, Francesco De Rose, Sebastian Fischer, et al.
Oncotarget|October 15, 2017
11C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancerHinrich Wieder, Ambros J Beer, Konstantin Holzapfel, et al.
European Urology|January 24, 2018
Efficacy, Predictive Factors, and Prediction Nomograms for <sup>68</sup>Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical ProstatectomyIsabel Rauscher, Charlotte Düwel, Bernhard Haller, et al.
Pageof 38

Showing results (111-120 of 377) with videos related to

Sort By:
Pageof 38
EJNMMI Research|January 31, 2022
Initial evaluation of [<sup>18</sup>F]-FACBC for PET imaging of multiple myelomaVolker Morath, Michael Heider, Markus Mittelhäuser, et al.
EJNMMI Research|February 3, 2026
Estimation of split renal function using [<sup>18</sup>F]-flotufolastat PET/CT compared with [<sup>68</sup>Ga]-PSMA-11 and [<sup>99m</sup>Tc]-MAG3 scintigraphyMichael Christian Marius Gammel, Charlotte Olufs, Kimberley Hansen, et al.
EJNMMI Physics|December 14, 2021
A population-based method to determine the time-integrated activity in molecular radiotherapyDeni Hardiansyah, Ade Riana, Peter Kletting, et al.
Seminars in Nuclear Medicine|December 9, 2025
The role of non-FDG agents in PET imaging of bladder cancerAlireza Safarian, Dina Muin, Lena Unterrainer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 18, 2025
Impact of baseline <sup>18</sup>F-flotufolastat PET bone tumor volume for prognosticating severe hematologic toxicity in patients with metastatic castration-resistant prostate Cancer receiving <sup>177</sup>Lu-PSMA-targeted radioligand therapyAmir Karimzadeh, Kimberley Hansen, Stefan Hein, et al.
European Urology Oncology|January 5, 2023
Prostate-specific Membrane Antigen-radioguided Surgery Facilitates Pelvic Lymph Node Dissection During Radical Prostatectomy for the Treatment of Locally Advanced Prostate Cancer with Regional Lymph Node MetastasesLukas Lunger, Lisa Steinhelfer, Philipp Korn, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 25, 2023
Delayed Imaging Improves Lesion Detectability in [<sup>99m</sup>Tc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate CancerChristoph Berliner, Lisa Steinhelfer, Maythinee Chantadisai, et al.
EJNMMI Radiopharmacy and Chemistry|February 26, 2024
Preclinical comparison of [<sup>177</sup>Lu]Lu-rhPSMA-10.1 and [<sup>177</sup>Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studiesAlexander Wurzer, Francesco De Rose, Sebastian Fischer, et al.
Oncotarget|October 15, 2017
11C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancerHinrich Wieder, Ambros J Beer, Konstantin Holzapfel, et al.
European Urology|January 24, 2018
Efficacy, Predictive Factors, and Prediction Nomograms for <sup>68</sup>Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical ProstatectomyIsabel Rauscher, Charlotte Düwel, Bernhard Haller, et al.
Pageof 38